RxDoctor Payments Data

Brianna Taylor, PA

Physician Assistant · Easton, PANPI 1023560059

Payments from drug & device makers

$1,549in general payments, 2019–2025

Across 16 payments — averaging $96.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$590
  • E.r. Squibb & Sons, L.L.C.$210
  • Madrigal Pharmaceuticals$150
  • Regeneron Healthcare Solutions, Inc.$125
  • Gilead$125
  • Takeda Pharmaceuticals U.S.A., Inc.$110
  • plus $240 from 3 others

What the payments were for

  • Food & beverage$1,549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,549 in reported general payments places this provider in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$18,011
Medicare patients
157
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide50$37,693
MotegrityPrucalopride Succinate13$6,780
Lubiprostone18$3,533
Pantoprazole Sodium245$3,117
ClenpiqSod Picosulf/Mag Ox/Citric Ac16$2,761
Sucralfate26$2,292
Famotidine161$2,106
Omeprazole118$1,630
CholestyramineCholestyramine (With Sugar)24$1,482
Dicyclomine Hcl53$1,035
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl40$623
Colestipol Hcl11$483
Esomeprazole Magnesium12$452
Ondansetron OdtOndansetron14$333
Ondansetron Hcl17$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$590$37,69350 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$110$6,78013 claims
Ferring Pharmaceuticals Inc.Clenpiq$82$2,76116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →